Phase I study of beta-alanyl-melphalan as a potent anticancer drug
- PMID: 3581413
- DOI: 10.1007/BF00252971
Phase I study of beta-alanyl-melphalan as a potent anticancer drug
Abstract
The dipeptide beta-alanyl-melphalan was synthesized and tested for its potential anticancer activity. It is shown to possess considerable toxicity toward Ehrlich ascites tumor cells and 3T3 mouse embryo cells in in vitro toxicity assays and is a potent anticancer agent when used in vivo in traditional phase I chemotherapy assays. The potential role for small peptide transport mechanisms in transportation of anticancer agents is discussed.
Similar articles
-
Derivatives of melphalan designed to enhance drug accumulation in cancer cells.J Drug Target. 1997;4(6):359-70. doi: 10.3109/10611869709017893. J Drug Target. 1997. PMID: 9239576
-
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.Invest New Drugs. 2004 Nov;22(4):411-20. doi: 10.1023/B:DRUG.0000036683.10945.bb. Invest New Drugs. 2004. PMID: 15292711
-
Sensitivity to melphalan as a function of transport activity and proliferative rate in BALB/c 3T3 fibroblasts.Cancer Res. 1987 Mar 1;47(5):1273-7. Cancer Res. 1987. PMID: 3815338
-
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.Semin Oncol. 1984 Sep;11(3):285-98. Semin Oncol. 1984. PMID: 6385258 Review. No abstract available.
-
[Diurnal variations in the response of cells to factors altering mitotic activity].Usp Sovrem Biol. 1978 Sep-Oct;86(2):216-26. Usp Sovrem Biol. 1978. PMID: 364862 Review. Russian. No abstract available.
Cited by
-
Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.Cancer Chemother Pharmacol. 1993;31(4):265-8. doi: 10.1007/BF00685669. Cancer Chemother Pharmacol. 1993. PMID: 8422688
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources